Derivation Web

source_a87687c4f2db4ca7

by researka:v2 · 2026-06-26 06:30:00.214402+04:00

{"content_hash": "sha256:7b872ec29d67243481f23d4db57722ef060a95ad2797fcba9e738f227a02fd34", "edges": [{"from": "3f0afbf6-e835-4b75-ae70-8dfca79bcb14", "to": "claim_1", "type": "contains_claim"}, {"from": "3f0afbf6-e835-4b75-ae70-8dfca79bcb14", "to": "claim_2", "type": "contains_claim"}, {"from": "3f0afbf6-e835-4b75-ae70-8dfca79bcb14", "to": "claim_3", "type": "contains_claim"}, {"from": "3f0afbf6-e835-4b75-ae70-8dfca79bcb14", "to": "claim_4", "type": "contains_claim"}, {"from": "3f0afbf6-e835-4b75-ae70-8dfca79bcb14", "to": "claim_5", "type": "contains_claim"}, {"from": "3f0afbf6-e835-4b75-ae70-8dfca79bcb14", "to": "claim_6", "type": "contains_claim"}, {"from": "3f0afbf6-e835-4b75-ae70-8dfca79bcb14", "to": "claim_7", "type": "contains_claim"}, {"from": "3f0afbf6-e835-4b75-ae70-8dfca79bcb14", "to": "claim_8", "type": "contains_claim"}, {"from": "3f0afbf6-e835-4b75-ae70-8dfca79bcb14", "to": "claim_9", "type": "contains_claim"}, {"from": "3f0afbf6-e835-4b75-ae70-8dfca79bcb14", "to": "claim_10", "type": "contains_claim"}, {"from": "3f0afbf6-e835-4b75-ae70-8dfca79bcb14", "to": "claim_11", "type": "contains_claim"}, {"from": "3f0afbf6-e835-4b75-ae70-8dfca79bcb14", "to": "claim_12", "type": "contains_claim"}, {"from": "3f0afbf6-e835-4b75-ae70-8dfca79bcb14", "to": "claim_13", "type": "contains_claim"}, {"from": "3f0afbf6-e835-4b75-ae70-8dfca79bcb14", "to": "claim_14", "type": "contains_claim"}, {"from": "3f0afbf6-e835-4b75-ae70-8dfca79bcb14", "to": "claim_15", "type": "contains_claim"}, {"from": "3f0afbf6-e835-4b75-ae70-8dfca79bcb14", "to": "claim_16", "type": "contains_claim"}, {"from": "3f0afbf6-e835-4b75-ae70-8dfca79bcb14", "to": "claim_17", "type": "contains_claim"}, {"from": "3f0afbf6-e835-4b75-ae70-8dfca79bcb14", "to": "claim_18", "type": "contains_claim"}, {"from": "3f0afbf6-e835-4b75-ae70-8dfca79bcb14", "to": "claim_19", "type": "contains_claim"}, {"from": "3f0afbf6-e835-4b75-ae70-8dfca79bcb14", "to": "claim_20", "type": "contains_claim"}, {"from": "3f0afbf6-e835-4b75-ae70-8dfca79bcb14", "to": "claim_21", "type": "contains_claim"}, {"from": "3f0afbf6-e835-4b75-ae70-8dfca79bcb14", "to": "claim_22", "type": "contains_claim"}, {"from": "3f0afbf6-e835-4b75-ae70-8dfca79bcb14", "to": "claim_23", "type": "contains_claim"}, {"from": "3f0afbf6-e835-4b75-ae70-8dfca79bcb14", "to": "claim_24", "type": "contains_claim"}, {"from": "3f0afbf6-e835-4b75-ae70-8dfca79bcb14", "to": "claim_25", "type": "contains_claim"}, {"from": "3f0afbf6-e835-4b75-ae70-8dfca79bcb14", "to": "claim_26", "type": "contains_claim"}, {"from": "3f0afbf6-e835-4b75-ae70-8dfca79bcb14", "to": "claim_27", "type": "contains_claim"}, {"from": "3f0afbf6-e835-4b75-ae70-8dfca79bcb14", "to": "claim_28", "type": "contains_claim"}, {"from": "3f0afbf6-e835-4b75-ae70-8dfca79bcb14", "to": "claim_29", "type": "contains_claim"}, {"from": "3f0afbf6-e835-4b75-ae70-8dfca79bcb14", "to": "claim_30", "type": "contains_claim"}], "nodes": [{"id": "3f0afbf6-e835-4b75-ae70-8dfca79bcb14", "title": "Adjacent Evidence Brief: Everolimus — full paper", "type": "publication"}, {"id": "claim_1", "text": "Evidence-honesty note: 24/27 retained sources are coded as null or no extracted directional signal; this corpus is non-supportive for clinical efficacy claims and hypothesis-generating only. Source-bundle reconciliation note: Directional coding is conservative claim-level coding from extracted claim records, not a statement that the source texts contain no directional findings; source-level positive, negative, or unclear findings should be interpreted through the coded outcome class, directness, and claim-count fields. The retained evidence has no direct interventional hard-endpoint evidence; indirect, review-level, adjacent, or mechanistic sources are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.", "type": "claim"}, {"id": "claim_2", "text": "This paper synthesizes evidence on Everolimus across 27 accepted source papers and 553 high-confidence extracted claims.", "type": "claim"}, {"id": "claim_3", "text": "The evidence profile contains no sources classified primarily as direct interventional hard-endpoint evidence, 25 adjacent clinical sources, and 2 mechanistic or model-system sources, with no load-bearing cross-study disagreements across the evidence base.", "type": "claim"}, {"id": "claim_4", "text": "Positive study-level signals are summarized in the mortality and survival outcome class, null signals in the contextual adjacent evidence, skeletal, fracture, and bone, immune and inflammation outcome classes, and negative signals in no dominant outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.", "type": "claim"}, {"id": "claim_5", "text": "The conclusion is that Everolimus remains a bounded geroscience case: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.", "type": "claim"}, {"id": "claim_6", "text": "This manuscript is reported as a Thin-corpus evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-everolimus-v06-DAILY-2026-06-26T02-23-24Z`.", "type": "claim"}, {"id": "claim_7", "text": "The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.", "type": "claim"}, {"id": "claim_8", "text": "Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification.", "type": "claim"}, {"id": "claim_9", "text": "Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, dosing and pharmacokinetics, immune and inflammation, mechanism, mortality and survival, safety and comorbidity, skeletal, fracture, and bone); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.", "type": "claim"}, {"id": "claim_10", "text": "Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.", "type": "claim"}, {"id": "claim_11", "text": "Evidence type metadata note: evidence-type labels are resolved against source excerpts; review, RCT/trial, and excerpt evidence are reclassified under the source classification map before claims are interpreted.", "type": "claim"}, {"id": "claim_12", "text": "Source-context verification gap: 5 source-bundle records have no DOI, PMID, PMCID, or trial identifier in the available metadata. They remain traceable source-bundle records, but are distinguished from externally identifier-verified peer-reviewed sources in the source-context map and do not independently upgrade evidence certainty.", "type": "claim"}, {"id": "claim_13", "text": "| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |", "type": "claim"}, {"id": "claim_14", "text": "| Everolimus / Contextual Adjacent Evidence | n=16; claims=353 | significant source statistic in 7/16 sources; receipt-level direction coded null | 9 indirect; 7 review | limited corpus depth in this outcome class |", "type": "claim"}, {"id": "claim_15", "text": "| Everolimus / Skeletal, Fracture, and Bone | n=3; claims=14 | reported statistic in 1/3 sources; receipt-level direction coded null | 3 review | limited corpus depth in this outcome class |", "type": "claim"}, {"id": "claim_16", "text": "| Everolimus / Immune and Inflammation | n=2; claims=38 | significant source statistic in 2/2 sources; receipt-level direction coded null | 1 indirect; 1 review | limited corpus depth in this outcome class |", "type": "claim"}, {"id": "claim_17", "text": "| Everolimus / Dosing and Pharmacokinetics | n=1; claims=79 | significant source statistic in 1/1 sources; receipt-level direction coded null | 1 mechanistic | single-source slice; hypothesis-generating |", "type": "claim"}, {"id": "claim_18", "text": "Oncology and cancer context: 17 sources; significant source statistic in 8/17 sources; receipt-level direction coded null.", "type": "claim"}, {"id": "claim_19", "text": "Dosing and pharmacokinetics context: 1 sources; significant source statistic in 1/1 sources; receipt-level direction coded null.", "type": "claim"}, {"id": "claim_20", "text": "Infectious-disease and immunology context: 1 sources; significant source statistic in 1/1 sources; receipt-level direction coded null.", "type": "claim"}, {"id": "claim_21", "text": "Transplant and fibrosis context: 1 sources; significant source statistic in 1/1 sources; receipt-level direction coded null.", "type": "claim"}, {"id": "claim_22", "text": "Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.", "type": "claim"}, {"id": "claim_23", "text": "Contextual Adjacent Evidence remains a separate Results slice for Everolimus (n=16; claims=353; significant source statistic in 7/16 sources; receipt-level direction coded null; 9 indirect; 7 review; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes.", "type": "claim"}, {"id": "claim_24", "text": "Dosing and Pharmacokinetics remains a separate Results slice for Everolimus (n=1; claims=79; significant source statistic in 1/1 sources; receipt-level direction coded null; 1 mechanistic; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes.", "type": "claim"}, {"id": "claim_25", "text": "Evidence for this outcome class is represented in the structured results table, but the retained narrative paragraphs were more strongly assigned to adjacent outcome classes. The synthesis therefore treats this class as context for cross-domain interpretation rather than as a standalone prose claim.", "type": "claim"}, {"id": "claim_26", "text": "Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.", "type": "claim"}, {"id": "claim_27", "text": "Several clinically meaningful outcomes in this synthesis are supported by only a single source, which prevents any within-corpus replication. Single-trial outcomes should therefore be treated as hypothesis-generating rather than as replicated findings.", "type": "claim"}, {"id": "claim_28", "text": "The enrolled populations are narrow and disease-specific, which constrains external validity. Healthy older adults without malignancy are effectively absent; the closest enrollment is the LB TORC Inhibition 2019 cohort of 652 older adults at increased respiratory-tract-infection risk , which used a related but distinct TORC1 inhibitor (RTB101), not everolimus. Generalizing safety or efficacy to non-oncologic, community-dwelling older adults therefore overreaches what these sources can support.", "type": "claim"}, {"id": "claim_29", "text": "Several clinically relevant claims are supported only by mechanistic or preclinical evidence, which the surrogate-endpoint caution articulated by Ioannidis 2005 explicitly flags as insufficient for hard-outcome inference. Translating these mechanistic signals into human clinical recommendations requires direct endpoint evidence that the curated corpus does not currently supply, and any such translation should be treated as a research priority rather than as a supported inference.", "type": "claim"}, {"id": "claim_30", "text": "The principal limitation is evidence-role imbalance. The retained corpus contains no sources classified primarily as direct clinical evidence, 25 adjacent clinical sources, and 2 mechanistic or model-system sources, which means causal interpretation depends on how much weight is assigned to each evidence tier.", "type": "claim"}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1186/s40360-025-01079-8", "effect": "not extracted", "endpoint": "not extracted", "id": "source_1", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Impact of aging on the pharmacokinetic profile of everolimus in male mice", "type": "source", "url": "https://doi.org/10.1186/s40360-025-01079-8", "year": 2026}, {"comparator": "not extracted", "directness": "primary", "doi": "10.3389/fimmu.2021.753412", "effect": "not extracted", "endpoint": "not extracted", "id": "source_2", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Everolimus Alleviates Renal Allograft Interstitial Fibrosis by Inhibiting Epithelial-to-Mesenchymal Transition Not Only via Inducing Autophagy but Also via Stabilizing IκB-α", "type": "source", "url": "https://doi.org/10.3389/fimmu.2021.753412", "year": 2022}, {"comparator": "not extracted", "directness": "primary", "doi": "10.3727/096504022X16418911579334", "effect": "not extracted", "endpoint": "not extracted", "id": "source_3", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "STAT3 Polymorphism Associates With mTOR Inhibitor-Induced Interstitial Lung Disease in Patients With Renal Cell Carcinoma", "type": "source", "url": "https://doi.org/10.3727/096504022X16418911579334", "year": 2022}, {"comparator": "not extracted", "directness": "primary", "doi": "10.3389/fonc.2022.874091", "effect": "not extracted", "endpoint": "not extracted", "id": "source_4", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma", "type": "source", "url": "https://doi.org/10.3389/fonc.2022.874091", "year": 2022}, {"comparator": "not extracted", "directness": "primary", "doi": "10.3389/fmolb.2022.981962", "effect": "not extracted", "endpoint": "not extracted", "id": "source_5", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Predicting clinical response to everolimus in ER+ breast cancers using machine-learning", "type": "source", "url": "https://doi.org/10.3389/fmolb.2022.981962", "year": 2022}, {"comparator": "not extracted", "directness": "primary", "doi": "10.3389/fonc.2020.01047", "effect": "not extracted", "endpoint": "not extracted", "id": "source_6", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Lanreotide Induces Cytokine Modulation in Intestinal Neuroendocrine Tumors and Overcomes Resistance to Everolimus", "type": "source", "url": "https://doi.org/10.3389/fonc.2020.01047", "year": 2020}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1007/s11547-022-01506-4", "effect": "not extracted", "endpoint": "not extracted", "id": "source_7", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "CT-based radiomics for prediction of therapeutic response to Everolimus in metastatic neuroendocrine tumors", "type": "source", "url": "https://doi.org/10.1007/s11547-022-01506-4", "year": 2022}, {"comparator": "not extracted", "directness": "review-level", "doi": null, "effect": "not extracted", "endpoint": "not extracted", "id": "source_8", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Everolimus and/or Exercise to Prevent Bone Loss in Postmenopausal Women", "type": "source", "url": null, "year": 2026}, {"comparator": "not extracted", "directness": "review-level", "doi": null, "effect": "not extracted", "endpoint": "not extracted", "id": "source_9", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Everolimus Aging Study", "type": "source", "url": null, "year": 2026}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1159/000516277", "effect": "not extracted", "endpoint": "not extracted", "id": "source_10", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "The Potential and Limitations of Precision Oncology: Lessons Learned from Whole-Exome Sequencing in an Exceptional Response to Everolimus in Advanced Renal Cell Carcinoma", "type": "source", "url": "https://doi.org/10.1159/000516277", "year": 2021}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1007/s00280-011-1653-5", "effect": "not extracted", "endpoint": "not extracted", "id": "source_11", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer", "type": "source", "url": "https://doi.org/10.1007/s00280-011-1653-5", "year": 2011}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1186/bcr3634", "effect": "not extracted", "endpoint": "not extracted", "id": "source_12", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer", "type": "source", "url": "https://doi.org/10.1186/bcr3634", "year": 2014}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1007/s12325-013-0060-1", "effect": "not extracted", "endpoint": "not extracted", "id": "source_13", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Everolimus Plus Exemestane in Postmenopausal Patients with HR + Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis", "type": "source", "url": "https://doi.org/10.1007/s12325-013-0060-1", "year": 2013}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1002/cam4.2460", "effect": "not extracted", "endpoint": "not extracted", "id": "source_14", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Everolimus‐containing therapy vs conventional therapy in the treatment of refractory breast cancer patients with PI3K/AKT/mTOR mutations: A retrospective study", "type": "source", "url": "https://doi.org/10.1002/cam4.2460", "year": 2019}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.1001/jamaoncol.2018.2262", "effect": "not extracted", "endpoint": "not extracted", "id": "source_15", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor–Positive, HER2-Negative Advanced Breast Cancer", "type": "source", "url": "https://doi.org/10.1001/jamaoncol.2018.2262", "year": 2018}, {"comparator": "not extracted", "directness": "review-level", "doi": null, "effect": "not extracted", "endpoint": "not extracted", "id": "source_16", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "LB2. TORC1 Inhibition with RTB101 as a Potential Pan-Antiviral Immunotherapy to Decrease the Incidence of Respiratory Tract Infections Due to Multiple Respiratory Viruses in Older Adults", "type": "source", "url": null, "year": 2019}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.1056/nejmoa1109653", "effect": "not extracted", "endpoint": "not extracted", "id": "source_17", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer", "type": "source", "url": "https://doi.org/10.1056/nejmoa1109653", "year": 2012}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.1200/jco.2005.23.16_suppl.7104", "effect": "not extracted", "endpoint": "not extracted", "id": "source_18", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Phase I/II trial of gefitinib and RAD001 (everolimus) in patients (pts) with advanced non-small cell lung cancer (NSCLC)", "type": "source", "url": "https://doi.org/10.1200/jco.2005.23.16_suppl.7104", "year": 2005}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.1200/jco.2012.30.15_suppl.556", "effect": "not extracted", "endpoint": "not extracted", "id": "source_19", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Everolimus (RAD) as treatment in breast cancer patients with bone metastases only: Results of the phase II RADAR study.", "type": "source", "url": "https://doi.org/10.1200/jco.2012.30.15_suppl.556", "year": 2012}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1158/0008-5472.can-06-4490", "effect": "not extracted", "endpoint": "not extracted", "id": "source_20", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "RAD001 (Everolimus) Delays Tumor Onset and Progression in a Transgenic Mouse Model of Ovarian Cancer", "type": "source", "url": "https://doi.org/10.1158/0008-5472.can-06-4490", "year": 2007}, {"comparator": "not extracted", "directness": "review-level", "doi": null, "effect": "not extracted", "endpoint": "not extracted", "id": "source_21", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis", "type": "source", "url": null, "year": 2012}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1159/000496984", "effect": "not extracted", "endpoint": "not extracted", "id": "source_22", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Everolimus and Bevacizumab in the Management of Recurrent, Progressive Intracranial NF2 Mutated Meningioma", "type": "source", "url": "https://doi.org/10.1159/000496984", "year": 2019}, {"comparator": "not extracted", "directness": "review-level", "doi": null, "effect": "not extracted", "endpoint": "not extracted", "id": "source_23", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Resistance Training and Rapamycin to Enhance Bone Formation in Postmenopausal Women", "type": "source", "url": null, "year": null}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.1200/jco.2014.58.3401", "effect": "not extracted", "endpoint": "not extracted", "id": "source_24", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Phase II Study of Everolimus and Letrozole in Patients With Recurrent Endometrial Carcinoma", "type": "source", "url": "https://doi.org/10.1200/jco.2014.58.3401", "year": 2015}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.3109/10428190903486220", "effect": "not extracted", "endpoint": "not extracted", "id": "source_25", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis", "type": "source", "url": "https://doi.org/10.3109/10428190903486220", "year": 2010}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.3233/kca-170020", "effect": "not extracted", "endpoint": "not extracted", "id": "source_26", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC)", "type": "source", "url": "https://doi.org/10.3233/kca-170020", "year": 2018}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.1182/blood.v110.11.121.121", "effect": "not extracted", "endpoint": "not extracted", "id": "source_27", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed Aggressive Non-Hodgkin Lymphoma (NHL).", "type": "source", "url": "https://doi.org/10.1182/blood.v110.11.121.121", "year": 2007}, {"comparator": "not extracted", "directness": "citation", "doi": null, "effect": "not extracted", "endpoint": "not extracted", "id": "source_28", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "**Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.", "type": "source", "url": null, "year": null}, {"comparator": "not extracted", "directness": "citation", "doi": null, "effect": "not extracted", "endpoint": "not extracted", "id": "source_29", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "**Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.", "type": "source", "url": null, "year": null}, {"comparator": "not extracted", "directness": "citation", "doi": null, "effect": "not extracted", "endpoint": "not extracted", "id": "source_30", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "**Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.", "type": "source", "url": null, "year": null}, {"comparator": "not extracted", "directness": "citation", "doi": null, "effect": "not extracted", "endpoint": "not extracted", "id": "source_31", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "**Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.", "type": "source", "url": null, "year": null}, {"comparator": "not extracted", "directness": "citation", "doi": null, "effect": "not extracted", "endpoint": "not extracted", "id": "source_32", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "LB TORC Inhibition 2019", "type": "source", "url": null, "year": null}, {"comparator": "not extracted", "directness": "citation", "doi": null, "effect": "not extracted", "endpoint": "not extracted", "id": "source_33", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Everolimus and or Exercise to Prevent 2026", "type": "source", "url": null, "year": null}, {"comparator": "not extracted", "directness": "citation", "doi": null, "effect": "not extracted", "endpoint": "not extracted", "id": "source_34", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Study to Determine the Safety 2012", "type": "source", "url": null, "year": null}, {"comparator": "not extracted", "directness": "citation", "doi": null, "effect": "not extracted", "endpoint": "not extracted", "id": "source_35", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Everolimus Aging Study 2026", "type": "source", "url": null, "year": null}, {"comparator": "not extracted", "directness": "citation", "doi": null, "effect": "not extracted", "endpoint": "not extracted", "id": "source_36", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Resistance Training and Rapamycin n.d.", "type": "source", "url": null, "year": null}, {"comparator": "not extracted", "directness": "citation", "doi": "10.1371/journal.pmed.0020124", "effect": "not extracted", "endpoint": "not extracted", "id": "source_37", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Ioannidis 2005", "type": "source", "url": "https://doi.org/10.1371/journal.pmed.0020124", "year": null}], "publication_id": "3f0afbf6-e835-4b75-ae70-8dfca79bcb14", "screening": {"excluded": 0, "exclusion_reasons": ["No PRISMA full-text exclusion-stage filter was applied."], "flow": ["identified", "screened", "excluded_with_reasons", "included"], "identified": 27, "included": 27, "included_or_retained": 27, "screened": 27, "wording": "27 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit."}}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "3f0afbf6-e835-4b75-ae70-8dfca79bcb14",
  "researka_submission_id": "128a3efa-aea0-44ed-9ad2-5ded7d3615c6",
  "sidecar_name": "claim_graph.json",
  "sidecar_url": "https://api.researka.org/publications/3f0afbf6-e835-4b75-ae70-8dfca79bcb14/sidecars/claim_graph.json"
}